Citadel Advisors
VNDA icon

Citadel Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Citadel Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$418K Buy
60,500
+40,400
+201% +$312K ﹤0.01% 9734
2025
Q4 		$177K Sell
20,100
-5,800
-22% -$31.9K ﹤0.01% 11140
2025
Q3 		$129K Sell
25,900
-29,200
-53% -$135K ﹤0.01% 11647
2025
Q2 		$260K Sell
55,100
-8,200
-13% -$35.9K ﹤0.01% 10119
2025
Q1 		$291K Buy
63,300
+54,300
+603% +$253K ﹤0.01% 9673
2024
Q4 		$43.1K Sell
9,000
-12,100
-57% -$58.1K ﹤0.01% 12546
2024
Q3 		$99K Sell
21,100
-43,200
-67% -$232K ﹤0.01% 11130
2024
Q2 		$363K Buy
64,300
+24,500
+62% +$127K ﹤0.01% 8726
2024
Q1 		$164K Buy
39,800
+20,200
+103% +$80.9K ﹤0.01% 10633
2023
Q4 		$82.7K Buy
19,600
+16,100
+460% +$65K ﹤0.01% 11175
2023
Q3 		$15.1K Sell
3,500
-700
-17% -$3.89K ﹤0.01% 12840
2023
Q2 		$27.7K Buy
4,200
+1,700
+68% +$10.9K ﹤0.01% 12437
2023
Q1 		$17K Sell
2,500
-14,600
-85% -$103K ﹤0.01% 13177
2022
Q4 		$126K Buy
+17,100
New +$167K ﹤0.01% 10866
2022
Q3 		– Sell
-10,300
Closed -$112K – 13685
2022
Q2 		$112K Sell
10,300
-1,300
-11% -$13.5K ﹤0.01% 11309
2022
Q1 		$131K Sell
11,600
-7,500
-39% -$98.6K ﹤0.01% 12003
2021
Q4 		$300K Sell
19,100
-7,200
-27% -$125K ﹤0.01% 10926
2021
Q3 		$451K Buy
26,300
+12,700
+93% +$222K ﹤0.01% 10128
2021
Q2 		$293K Buy
13,600
+3,100
+30% +$55.5K ﹤0.01% 11325
2021
Q1 		$158K Buy
+10,500
New +$170K ﹤0.01% 11980
2020
Q4 		– Sell
-13,500
Closed -$130K – 11570
2020
Q3 		$130K Sell
13,500
-1,100
-8% -$11.8K ﹤0.01% 9106
2020
Q2 		$167K Sell
14,600
-2,500
-15% -$28.3K ﹤0.01% 8668
2020
Q1 		$177K Sell
17,100
-1,100
-6% -$13.6K ﹤0.01% 8133
2019
Q4 		$299K Buy
+18,200
New +$275K ﹤0.01% 7589
2019
Q2 		– Sell
-39,300
Closed -$723K – 9917
2019
Q1 		$723K Buy
39,300
+24,300
+162% +$554K ﹤0.01% 6159
2018
Q4 		$392K Sell
15,000
-4,300
-22% -$101K ﹤0.01% 6803
2018
Q3 		$443K Buy
+19,300
New +$394K ﹤0.01% 6894
2018
Q1 		– Sell
-12,000
Closed -$182K – 8833
2017
Q4 		$182K Buy
+12,000
New +$178K ﹤0.01% 7178
2016
Q4 		– Sell
-18,800
Closed -$313K – 7887
2016
Q3 		$313K Buy
18,800
+2,200
+13% +$29.6K ﹤0.01% 5616
2016
Q2 		$186K Buy
+16,600
New +$161K ﹤0.01% 5891
2016
Q1 		– Sell
-16,800
Closed -$156K – 8037
2015
Q4 		$156K Sell
16,800
-11,800
-41% -$118K ﹤0.01% 6155
2015
Q3 		$323K Buy
28,600
+8,600
+43% +$105K ﹤0.01% 5460
2015
Q2 		$254K Buy
20,000
+8,100
+68% +$87.4K ﹤0.01% 5993
2015
Q1 		$111K Sell
11,900
-8,400
-41% -$94.9K ﹤0.01% 6761
2014
Q4 		$291K Buy
20,300
+10,500
+107% +$124K ﹤0.01% 5487
2014
Q3 		$102K Buy
9,800
+7,000
+250% +$91.8K ﹤0.01% 6397
2014
Q2 		$45K Sell
2,800
-12,800
-82% -$170K ﹤0.01% 6824
2014
Q1 		$254K Sell
15,600
-24,600
-61% -$350K ﹤0.01% 5224
2013
Q4 		$499K Sell
40,200
-14,400
-26% -$145K ﹤0.01% 4021
2013
Q3 		$599K Buy
54,600
+35,500
+186% +$379K ﹤0.01% 3608
2013
Q2 		$154K Buy
+19,100
New +$129K ﹤0.01% 4886

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's VNDA Position: Q1 2026 in Review

Citadel Advisors opened a new position in Vanda Pharmaceuticals (VNDA) in Q1 2026: 633,354 shares worth $4.38M. The stake represents ﹤0.01% of the portfolio and ranks #4563 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in VNDA as recently as Q3 2025.

Citadel Advisors first reported a position in VNDA in Q2 2013 and has held it in 49 quarters since. The position peaked at $14.1M in Q3 2017. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Citadel Advisors held 633,354 shares of Vanda Pharmaceuticals worth $4.38M as of Q1 2026.
  • Vanda Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
  • Vanda Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4563 holding.
  • Citadel Advisors first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • Citadel Advisors's Vanda Pharmaceuticals position peaked at $14.1M in Q3 2017.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.